CELLDEX THERAPEUTICS, INC.
CELLDEX THERAPEUTICS, INC.
HAMPTON, NJ
Loading...
Price History
Market Data
| Market Cap | 2.22B |
| P/E Ratio | - |
| P/B Ratio | 4.20 |
| EPS | -3.90 |
| Dividend Yield | - |
| D/E Ratio | 0.11 |
| Current Ratio | 10.49 |
| Currency | USD |
Key Financial Metrics
2.97M
Revenue
-258.76M
Net Income
-3.90
EPS (Diluted)
-367.67M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-9675.6%
Net Profit Margin
-8712.4%
EBITDA
-281.38M
Returns & Efficiency
Return on Assets (ROA)
-44.4%
Return on Equity (ROE)
-49.1%
Dividend Yield
-
EPS
-3.90
Financial Health
Total Assets
582.98M
Total Debt
-
Debt to Equity
0.11x
Current Ratio
10.49
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | HAMPTON, NJ |
| Fiscal Year | 2025 |
Peers
44.92B
P/E: --
9.05B
P/E: --
VENAXIS, INC.
RIOT
9.05B
P/E: --
BIOPTIX, INC.
RIOT
9.05B
P/E: --
9.05B
P/E: --
5.94B
P/E: 28.0
ARCA BIOPHARMA, INC.
ORKA
3.76B
P/E: --
3.76B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$2.22B
P/E Ratio (TTM)-
Price to Book4.20
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-9675.6%
Net Margin-8712.4%
ROE-49.1%
ROA-44.4%
Leverage & Liquidity
Debt to Equity0.11
Current Ratio10.49
Total Debt-
Total Assets$582.98M
Stockholders' Equity$527.16M
Income Statement (FY 2025)
Revenue$2.97M
Gross Profit-
Operating Income$-287.37M
Net Income$-258.76M
EPS (Diluted)$-3.90
Cash Flow (FY 2025)
Free Cash Flow$-367.67M
Cash & Equivalents$28.87M
Revenue Growth92.2%
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 53 FRONTAGE ROAD SUITE 220 HAMPTON, NJ 08827 |
| Phone | 908-200-7500 |
| Incorporated | DE, US |
| EIN | 133191702 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 66.57M |
| Stockholders' Equity | $527.16M |
| Cash & Equivalents | $28.87M |
Recent Filings
View All
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2026-05-07
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-05-07
Local
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-05-06
Local
ARS
Annual Report to Shareholders
Annual report furnished to shareholders
Filed: 2026-04-29
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2026-04-29
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-04-29
Local
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-03-26
Local
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-03-10
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-02-25
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-02-25
Local
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-02-10
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-02-09
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-10
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-07
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-05-08
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | CELLDEX THERAPEUTICS, INC. |
| Ticker | CLDX |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | HAMPTON, NJ |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 2.22B |
| Revenue | 2.97M |
| Net Income | -258.76M |
| P/E Ratio | - |
| EPS | -3.90 |
| Net Margin | -8712.4% |
| ROE | -49.1% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...